| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | zanzalintinib in combination with atezolizumab adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-EGFR therapy | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology | |
PDUFA Date example | zanzalintinib in combination with atezolizumab adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-EGFR therapy | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology | |
PDUFA Date example | zanzalintinib in combination with atezolizumab adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-EGFR therapy | PDUFA | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Exelixis, Inc.
$54.55
+0.47 (+0.87%)
B 66Pipeline Score Fair Value Biotech · Commercial
Market Cap
13.52 B
EPS
3.47
P/E Ratio
15.71 $
Value Trade
177.52 M
2.69 %
Week
-2.26 %
1 Month
9.14 %
3 Month
20.85 %
6 Month
105.95 %
5 Year
178.61 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
2.42 M
52 Week Range
33.76 - 57.57
% held by Insiders
3.18 %
% held by Institutions
105.84 %
Enterprise Value
12.13 B
Total Shares
247.78 M
Short %
11.98 %
Float Shares
243.54 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Exelixis, Inc.
398Total events
6Upcoming
130Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T2Management Change
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | zanzalintinib in combination with atezolizumab | Phase 3 data readout | Phase 3 | — | – | – | – |
2026-06-30 | zanzalintinib in combination with atezolizumab | Phase 3 data readout | Phase 3 | — | – | – | – |
2026-06-30 | zanzalintinib in combination with atezolizumab | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
B66
Pipeline Score $4.5B
Pipeline ValueFair Value
Valuation Signal17
Drugs Scored1.1x
rNPV / MCap Top 94%
Mid Cap (rank 57 of 933)
Percentile RankExelixis, Inc. holds a solid B-grade pipeline (66/100), with $5.3B risk-adjusted pipeline value, led by Zanzalintinib in Aggressive Variant Prostate Carcinoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zanzalintinib Small molecule | Colorectal Cancer | Phase 3 | NCT07750158 | 42% | $1.1B | NOT YET_RECRUITING | 600 | VERY_FAST | C (59) | Apr 5, 2030 | - | LOW Aug 6, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CABOMETYX | neuroendocrine tumors | Phase 3 | 2026-05-30 | non functional NET: hazard ratio 0.26, median PFS cabozantinib 9.4 months, median PFS placebo 3.1 months; functional NET: hazard ratio 0.4, median PFS cabozantinib 12.7 months, median PFS placebo 5.4 months Read More | Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 Read More | |
CABOMETYX | neuroendocrine tumors | Phase 3 | 2026-05-30 | non functional NET: hazard ratio 0.26, median PFS cabozantinib 9.4 months, median PFS placebo 3.1 months; functional NET: hazard ratio 0.4, median PFS cabozantinib 12.7 months, median PFS placebo 5.4 months Read More | Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 Read More | |
CABOMETYX | neuroendocrine tumors | Phase 3 | 2026-05-30 | non functional NET: hazard ratio 0.26, median PFS cabozantinib 9.4 months, median PFS placebo 3.1 months; functional NET: hazard ratio 0.4, median PFS cabozantinib 12.7 months, median PFS placebo 5.4 months Read More | Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EXEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EXEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EXEL▼ -7.9%on this news
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Exelixis, Inc. has announced its financial results for the second quarter of 2026, highlighting progress in achieving corporate objectives. The company is focused on its strategic goals and has outlined milestones in its commercial, clinical, and pipeline development. CEO Michael M. Morrissey emphasized the company's commitment to executing its business strategy.
Read more →EXELExelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
Exelixis, Inc. will release its second quarter 2026 financial results on August 5, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. ET for management to discuss the results and provide a business update. Access to the event will be available online.
Read more →EXELExelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Exelixis has provided an update regarding the Phase 3 STELLAR-303 trial, which is evaluating the efficacy of Zanzalintinib in combination with an immune checkpoint inhibitor for patients suffering from metastatic colorectal cancer. The trial aims to assess the potential benefits of this combination therapy in improving patient outcomes.
Read more →EXELExelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Exelixis has announced results from a subgroup analysis of the Phase 3 CABINET trial, which evaluates CABOMETYX in neuroendocrine tumors. The findings were presented at ASCO 2026, highlighting the drug's potential applications. Further details about the results and implications for treatment were not provided in the announcement.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June 2026
Exelixis, Inc. has announced its participation in fireside chats at upcoming investor conferences in June 2026. These presentations will be accessible via their website, with replays available for 30 days. The company emphasizes its commitment to advancing cancer care through innovative treatments and a robust pipeline.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Exelixis will host fireside chats during upcoming investor conferences in June. The events aim to engage with investors and discuss the company's strategies and developments. Specific details about the conferences or topics to be covered were not provided in the announcement.
Read more →EXELExelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis has announced its participation in ASCO 2026, where it will present ongoing studies related to various tumor types. The presentations aim to showcase the company's advancements in cancer research. Specific details about the studies or findings were not disclosed in the announcement.
Read more →EXELExelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis has announced a clinical development collaboration with Merck for the Phase 3 STELLAR-316 pivotal trial, focusing on patients with colorectal cancer. This partnership aims to enhance treatment options and advance research in this critical area. The collaboration signifies a strategic move to leverage combined expertise in oncology.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026
Exelixis, Inc. has announced its participation in fireside chats at upcoming investor conferences in May 2026. The presentations will be available via webcast on the company's website, with replays accessible for at least 30 days. This initiative highlights Exelixis's commitment to transparency and engagement with its investor community.
Read more →EXEL▼ -5.1%on this newsshared move
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
Exelixis will host fireside chats during upcoming investor conferences in May. The events aim to engage with investors and provide insights into the company's strategies and developments. Specific details about the conferences and topics to be discussed were not provided in the article.
Read more →EXELExelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
Exelixis has announced its financial results for the first quarter of 2026 along with a corporate update. However, the article lacks specific details regarding the financial performance or any significant corporate developments. The information provided is minimal and does not elaborate on the implications of these results.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Andrew Peters SVP, Strategy Investor Relations Exelixis, Inc. 650-837-7248 apeters exelixis.com Exelixis Announces First Quar
Exelixis, Inc. reported financial results for the first quarter of 2026, with total revenues reaching $610.8 million, a significant increase from the previous year. The company provided updates on its ongoing research and development activities, including the FDA's acceptance of a New Drug Application for zanzalintinib in metastatic colorectal cancer. Additionally, Exelixis announced a stock repurchase program of up to $750 million to further support shareholder value. The financial results reflect stable growth in net product revenues, particularly from the cabozantinib franchise.
Read more →EXEL▲ +5.2%on this news
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
Exelixis, Inc. will release its first quarter 2026 financial results on May 5, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide a business update. The event can be accessed via the company's website, with a replay available for one year.
Read more →EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March 2026
Exelixis, Inc. has announced its participation in fireside chats at upcoming investor conferences in March 2026. The webcasts will be available on their website, allowing investors to access the discussions and replays for 30 days. This initiative highlights Exelixis's commitment to transparency and engagement with its stakeholders.
Read more →EXELExelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Exelixis, Inc. announced strong financial results for Q4 and FY 2025, with total revenues reaching $599 million and $2.320 billion, respectively. The cabozantinib franchise generated significant growth, particularly in renal cell carcinoma and neuroendocrine tumors. Looking ahead, Exelixis is focused on expanding its oncology portfolio, particularly with zanzalintinib, which has a pending NDA for metastatic colorectal cancer. The company anticipates a milestone-rich 2026 with key clinical trial results expected.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Andrew Peters SVP, Strategy and Investor Relations Exelixis, Inc. 650-837-7248 apeters exelixis.com Exelixis Announces Fourth
Exelixis, Inc. reported strong financial results for the fourth quarter and fiscal year 2025, with total revenues reaching $599 million in Q4 and $2.320 billion for the year. The cabozantinib franchise saw robust demand, contributing to substantial revenue growth, especially in the renal cell carcinoma and neuroendocrine tumor markets. CEO Michael M. Morrissey highlighted upcoming key clinical readouts and the potential for further developments with zanzalintinib, indicating a promising outlook for 2026.
Read more →EXELExelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Exelixis announced that the FDA has accepted its New Drug Application for zanzalintinib in combination with atezolizumab for treating metastatic colorectal cancer. This application is based on positive results from the phase 3 STELLAR-303 trial, which showed significant improvements in overall survival. The FDA has set a target action date of December 3, 2026, for the review.
Read more →EXELExelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Exelixis, Inc. will announce its fourth quarter and fiscal year 2025 financial results on February 10, 2026. Following the release, a conference call and webcast will be held at 5:00 p.m. ET to discuss the results and provide a business update. The event will be accessible via the company's website.
Read more →EXELInvestor Contacts Andrew Peters SVP, Strategy and Investor Relations Exelixis, Inc. 650-837-7248 apeters exelixis.com Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Media Contact Ha
Exelixis, Inc. has reported preliminary financial results for fiscal year 2025, highlighting approximately $2.123 billion in net product revenues. The company provided optimistic financial guidance for 2026, forecasting net product revenues between $2.325 billion and $2.425 billion. CEO Michael Morrissey emphasized the company's commitment to developing key oncology franchises and advancing its drug pipeline. Zanzalintinib, which is under FDA review, could significantly impact future revenues, although guidance does not currently include its potential approval.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Exelixis Announces Thi
Exelixis, Inc. announced its third-quarter 2025 financial results, reporting total revenues of $597.8 million and a strong performance from its cabozantinib franchise, particularly in renal cell carcinoma and neuroendocrine tumors. The company intends to submit a new drug application for zanzalintinib by year-end following positive trial results. However, it also reported restructuring expenses related to a corporate reorganization and a decrease in collaboration revenues compared to the previous year.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Exelixis Announces Sec
Exelixis, Inc. reported its financial results for the second quarter of 2025, highlighting total revenues of $568.3 million, up from $637.2 million in Q2 2024. The company noted strong performance from its cabozantinib franchise, with U.S. net product revenues reaching $520.0 million. Furthermore, Exelixis announced positive results from the STELLAR-303 pivotal study, and updates were provided on the launch of CABOMETYX in advanced neuroendocrine tumors (NET). However, collaboration revenues experienced a marked decline compared to the previous year.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Exelixis Announces Fir
Exelixis, Inc. reported strong financial results for the first quarter of 2025, with total revenues of $555.4 million and a significant increase in net product revenues driven by CABOMETYX. The company has raised its revenue guidance for the year by $100 million, reflecting positive market demand and sales growth. Exelixis also noted the rapid mobilization for the CABOMETYX launch in advanced neuroendocrine tumors and its plans for multiple pipeline milestones later in 2025. However, there were decreases in collaboration revenues, and operating costs, particularly in R&D and SG&A, could pose challenges moving forward.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Exelixis Announces a N
Exelixis, Inc. has announced the authorization of a new $500 million stock repurchase program expected to commence after the current program is completed in Q2 2025. This move follows the company's previous repurchases totaling over $1.2 billion, reflecting its commitment to enhance shareholder value. Exelixis continues to innovate within the oncology space with a focus on expanding its pipeline of cancer treatments. However, the execution of this program is subject to market conditions and other factors that could impact the timing and amount of repurchased shares.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Exelixis Announces Fou
Exelixis, Inc. announced its financial results for the fourth quarter and fiscal year 2024, revealing a total revenue of $567 million for the quarter and $2.17 billion for the year. The cabozantinib franchise was a major contributor, generating $1.81 billion in U.S. net product revenues for the fiscal year. The company highlighted ongoing developments in its pipeline, including expected pivotal data for new cancer treatments in 2025. With a positive outlook for future growth, Exelixis aims to enhance care standards for cancer patients.
Read more →EXELInvestor Contacts Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Media Contact
Exelixis, Inc. has announced its preliminary unaudited financial results for the fiscal year 2024, showing significant revenues and providing optimistic financial guidance for 2025. The company expects a revenue increase driven by its cabozantinib franchise and multiple upcoming data readouts for its pipeline. Additionally, Exelixis is preparing for a potential FDA approval for cabozantinib's expansion into treating neuroendocrine tumors, with a notable target action date set for April 2025. The company also highlights its commitment to building an oncology business while ensuring strong capital allocation strategies.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian exelixis.com Exelixis Announces Third
Exelixis, Inc. reported strong financial results for Q3 2024, with total revenues reaching $539.5 million, driven by net product revenues from cabozantinib. The company has received a favorable ruling related to cabozantinib patent litigation, enhancing its market position. Additionally, Exelixis announced a collaboration with Merck to advance zanzalintinib, which is expected to contribute to future growth. The company has raised its 2024 revenue guidance reflecting confidence in ongoing commercial performance and pipeline developments.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian exelixis.com Exelixis Announces First
Exelixis, Inc. reported its financial results for Q1 2024, showing total revenues of $425 million, up from $408.8 million in Q1 2023. The company highlighted its progress in clinical development, including ongoing pivotal trials and plans for Investigational New Drug filings in 2024. Despite reporting restructuring expenses of $32.8 million, Exelixis is focused on expanding its cabozantinib franchise and enhancing its research and commercial strategies. The financial guidance for 2024 remains unchanged, with projected revenues between $1.825 billion and $1.925 billion.
Read more →EXELDocument Contacts Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Exelixis Anno
Exelixis, Inc. has reported robust financial results for the fourth quarter and fiscal year 2023, with total revenues of $1.83 billion. The company is focusing on expanding the cabozantinib franchise into neuroendocrine tumors and metastatic prostate cancer, driven by positive clinical data. Despite successes, they experienced a decline in collaboration revenues and ongoing legal challenges. Exelixis is committed to advancing a diverse pipeline and maintaining a strong financial position through potential restructuring.
Read more →EXELDocument Investor Contacts Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Medi
Exelixis, Inc. released its preliminary financial results for fiscal year 2023, reporting $1.630 billion in revenues from its cabozantinib franchise. For fiscal year 2024, the company projects net product revenues between $1.650 billion to $1.750 billion and plans to implement a corporate restructuring that will reduce its workforce by about 175 employees. Exelixis has also appointed two new experienced board members and announced a $450 million share repurchase program for 2024, aiming to enhance its operational efficiency and focus resources on advancing its drug pipeline.
Read more →EXELInvestor Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Media Cont
Exelixis, Inc. announced the immediate resignation of Lance Willsey, M.D. from its Board of Directors. The Board supports Willsey's decision and is recommending that shareholders vote in favor of the remaining nominees for directors at the upcoming 2023 Annual Meeting. This resignation is believed to conclude Farallon Capital Management's proxy campaign against the company. Exelixis continues to prioritize the development of innovative cancer therapies while executing its Board refreshment strategy.
Read more →EXELDocument Contacts Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com EXELIXIS ANNO
Exelixis, Inc. announced its financial results for Q4 and full year 2022, reporting total revenues of $423.9 million for the quarter and $1.61 billion for the full year. The cabozantinib franchise led the way with U.S. net product revenues of $1.40 billion. Despite an increase in revenues, the company reported a GAAP net loss for Q4 2022. Looking ahead, Exelixis plans to advance its biotherapeutic pipeline and initiate Phase 3 studies in 2023.
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com EXELIXIS ANNOUNCES FIR
Chief Financial Officer csenner exelixis.com EVP, Public Affairs Investor Relations shubbard exelixis.com EXELIXIS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 milli
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com EXELIXIS ANNOUNCES FOU
Chief Financial Officer csenner exelixis.com EVP, Public Affairs Investor Relations shubbard exelixis.com EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $451.1 Million for the Fourth Quarter of 2021,
Read more →EXELChris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner exelixis.com Susan Hubbard EVP, Public Affairs Investor Relations Exelixis, Inc. 650-837-8194 shubbard exelixis.com EXELIXIS ANNOUNCES THI
Chief Financial Officer csenner exelixis.com EVP, Public Affairs Investor Relations shubbard exelixis.com EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Milli
Read more →EXELExelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma | Exelixis, Inc.
Exelixis announced FDA approval for CABOMETYX in combination with OPDIVO as a first-line treatment for advanced renal cell carcinoma, based on positive results from the CheckMate -9ER trial, which showed significant improvements in overall survival and progression-free survival compared to sunitinib.
Read more →EXELExelixis Files Second Complaint in Patent Infringement Lawsuit against MSN Pharmaceuticals, Inc.
Chief Financial Officer csenner@exelixis.com EVP, Public Affairs & Investor Relations shubbard@exelixis.com EXELIXIS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $259.5 Million, Cabozantinib Franchise Revenues of $178.7 Mi
Read more →EXELExelixis Partner Takeda Pharmaceutical Company Limited (Takeda) Receives Approval in Japan for CABOMETYX Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Ce
Chief Financial Officer csenner@exelixis.com EVP, Public Affairs & Investor Relations shubbard@exelixis.com EXELIXIS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenue of $226.9 Million, Cabozantinib Franchise Revenue of $193.9 Milli
Read more →EXELDocument Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com EXELIXIS A
Chief Financial Officer csenner@exelixis.com EVP, Public Affairs & Investor Relations shubbard@exelixis.com EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenue of $240.3 Million for the Fourth Quarter of 2019,
Read more →EXELDocument Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance - Company announces antici
Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance - Company announces anticipated timelines for data readouts from six cabozantinib potentially
Read more →EXELExelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma | Exelixis, Inc.
Exelixis announced FDA approval for CABOMETYX tablets as a first-line treatment for previously untreated advanced renal cell carcinoma, showing significant improvement in progression-free survival compared to sunitinib. The company is ready to support the expanded indication immediately.
Read more →EXELExelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy | Exelixis, Inc.
Exelixis announced FDA approval of CABOMETYX for advanced renal cell carcinoma, marking it as the first therapy to show significant improvements in overall and progression-free survival. The approval is based on the METEOR trial results, providing a new treatment option for patients who have received prior anti-angiogenic therapy.
Read more →EXELFDA Approves COMETRIQ™ (Cabozantinib) for Treatment of Progressive, Metastatic Medullary Thyroid Cancer | Exelixis, Inc.
The FDA has approved COMETRIQ (cabozantinib) for treating progressive, metastatic medullary thyroid cancer, marking a significant advancement in patient care. The approval is based on a clinical trial showing improved progression-free survival. Exelixis plans to launch the drug promptly.
Read more →Competitive Position
How EXEL ranks across every disease it competes inCompetitive Position is a premium feature
See how EXEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial